PRTK - パラテック・ファ―マシュ―ティカルズ (Paratek Pharmaceuticals Inc. ) パラテック・ファ―マシュ―ティカルズ

 PRTKのチャート


 PRTKの企業情報

symbol PRTK
会社名 Paratek Pharmaceuticals Inc (パラテック・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 パラテック・ファーマスーティカルズ(Paratek Pharmaceuticals Inc.)は臨床段階のバイオ医薬品会社である。同社はテトラサイクリン化学に基づいた治療薬の開発と商品化に従事する。同社の製品候補は抗菌剤オマダサイクリンおよびサルサイクリンである。オマダサイクリンは、地域社会が獲得した細菌感染症に罹患している患者の経験的な単独療法の選択肢として使用するために開発された抗生物質である。サリシクリンは、にきびおよび酒さの治療に使用するために設計されたテトラサイクリン由来化合物である。その他の製品候補は、テトラサイクリン由来の分子実体であり、テトラサイクリンクラスの認識された免疫調節、抗炎症および他の有益な特性を利用するように設計されている。これらの研究段階プログラムには、多発性硬化症、脊髄性筋萎縮、慢性関節リウマチおよび炎症性腸疾患などの全身性炎症性疾患のための製品候補が含まれる。   パラテック・ファ―マシュ―ティカルズは米国のバイオ医薬品会社。細菌感染症用抗生物質の開発と商業化に従事。製品候補には、急性皮膚・皮膚組織感染症や尿路感染症治療用のテトラサイクリン系抗生物質オマダサイクリン、およびにきび・ロザケア治療用のテトラサイクリン系抗生物質WC3035がある。本社はマサチュ―セッツ州。   
本社所在地 75 Park Plaza Boston MA 02116 USA
代表者氏名 Michael F. Bigham マイケル・F・ビガム
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 617-807-6600
設立年月日 36923
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 83人
url www.transcept.com
nasdaq_url https://www.nasdaq.com/symbol/prtk
adr_tso
EBITDA EBITDA(百万ドル) -94.63600
終値(lastsale) 10.31
時価総額(marketcap) 327132681.19
時価総額 時価総額(百万ドル) 296.35490
売上高 売上高(百万ドル) 5.13400
企業価値(EV) 企業価値(EV)(百万ドル) 250.86190
当期純利益 当期純利益(百万ドル) -100.70000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Paratek Pharmaceuticals Inc revenues decreased 99% to $50K. Net loss increased 25% to $57.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects General and administrative - Balancing increase of 51% to $18.9M (expense) Interest expense increase of 95% to $4.4M (expense).

 PRTKのテクニカル分析


 PRTKのニュース

   The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs  2021/02/10 12:34:42 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) AngioDynamics, Inc. (NASDAQ: ANGO ) argenx SE – ADR (NASDAQ: ARGX ) Arcus Biosciences Inc (NYSE: RCUS ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Assertio Holdings Inc (NASDAQ: ASRT ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) ChemoCentryx Inc (NASDAQ: CCXI ) Chimerix Inc (NASDAQ: CMRX ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) DarioHealth Corp (NASDAQ: DRIO ) Edap Tms SA (NASDAQ: EDAP ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Haemonetics Corporation (NYSE: HAE ) Fulgent Genetics Inc (NASDAQ: FLGT ) Halozyme Therapeutics, Inc.
   Paratek Pharmaceuticals Receives $60 Million Non-Recourse Loan from R-Bridge Healthcare Investment Advisory, Ltd., an affiliate of CBC Group  2021/01/04 22:00:00 GlobeNewswire
Proceeds Used to Prepay Outstanding Loan with Hercules Capital, Inc.
   Insider Selling: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Chairman Sells $127,442.15 in Stock  2020/12/18 14:04:41 Watchlist News
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Chairman Michael Bigham sold 18,337 shares of the company’s stock in a transaction on Friday, December 11th. The shares were sold at an average price of $6.95, for a total transaction of $127,442.15. Following the transaction, the chairman now owns 572,580 shares of the company’s stock, valued at $3,979,431. The transaction […]
   Insider Selling: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Chairman Sells $174,882.73 in Stock  2020/12/18 12:14:41 Watchlist News
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Chairman Michael Bigham sold 26,063 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Monday, December 14th. The shares were sold at an average price of $6.71, for a total transaction of $174,882.73. Following the sale, the chairman now directly owns 572,580 shares in the company, valued at approximately […]
   William M. Haskel Sells 4,814 Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock  2020/12/16 12:38:41 Watchlist News
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) General Counsel William M. Haskel sold 4,814 shares of the business’s stock in a transaction dated Friday, December 11th. The stock was sold at an average price of $6.95, for a total transaction of $33,457.30. Following the sale, the general counsel now owns 210,109 shares in the company, valued at $1,460,257.55. […]
   The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs  2021/02/10 12:34:42 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) AngioDynamics, Inc. (NASDAQ: ANGO ) argenx SE – ADR (NASDAQ: ARGX ) Arcus Biosciences Inc (NYSE: RCUS ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Assertio Holdings Inc (NASDAQ: ASRT ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) ChemoCentryx Inc (NASDAQ: CCXI ) Chimerix Inc (NASDAQ: CMRX ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) DarioHealth Corp (NASDAQ: DRIO ) Edap Tms SA (NASDAQ: EDAP ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Haemonetics Corporation (NYSE: HAE ) Fulgent Genetics Inc (NASDAQ: FLGT ) Halozyme Therapeutics, Inc.
   Paratek Pharmaceuticals Receives $60 Million Non-Recourse Loan from R-Bridge Healthcare Investment Advisory, Ltd., an affiliate of CBC Group  2021/01/04 22:00:00 GlobeNewswire
Proceeds Used to Prepay Outstanding Loan with Hercules Capital, Inc.
   Insider Selling: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Chairman Sells $127,442.15 in Stock  2020/12/18 14:04:41 Watchlist News
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Chairman Michael Bigham sold 18,337 shares of the company’s stock in a transaction on Friday, December 11th. The shares were sold at an average price of $6.95, for a total transaction of $127,442.15. Following the transaction, the chairman now owns 572,580 shares of the company’s stock, valued at $3,979,431. The transaction […]
   Insider Selling: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Chairman Sells $174,882.73 in Stock  2020/12/18 12:14:41 Watchlist News
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Chairman Michael Bigham sold 26,063 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Monday, December 14th. The shares were sold at an average price of $6.71, for a total transaction of $174,882.73. Following the sale, the chairman now directly owns 572,580 shares in the company, valued at approximately […]
   William M. Haskel Sells 4,814 Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock  2020/12/16 12:38:41 Watchlist News
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) General Counsel William M. Haskel sold 4,814 shares of the business’s stock in a transaction dated Friday, December 11th. The stock was sold at an average price of $6.95, for a total transaction of $33,457.30. Following the sale, the general counsel now owns 210,109 shares in the company, valued at $1,460,257.55. […]
   The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs  2021/02/10 12:34:42 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) AngioDynamics, Inc. (NASDAQ: ANGO ) argenx SE – ADR (NASDAQ: ARGX ) Arcus Biosciences Inc (NYSE: RCUS ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Assertio Holdings Inc (NASDAQ: ASRT ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) ChemoCentryx Inc (NASDAQ: CCXI ) Chimerix Inc (NASDAQ: CMRX ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) DarioHealth Corp (NASDAQ: DRIO ) Edap Tms SA (NASDAQ: EDAP ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Haemonetics Corporation (NYSE: HAE ) Fulgent Genetics Inc (NASDAQ: FLGT ) Halozyme Therapeutics, Inc.
   Paratek Pharmaceuticals Receives $60 Million Non-Recourse Loan from R-Bridge Healthcare Investment Advisory, Ltd., an affiliate of CBC Group  2021/01/04 22:00:00 GlobeNewswire
Proceeds Used to Prepay Outstanding Loan with Hercules Capital, Inc.
   Insider Selling: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Chairman Sells $127,442.15 in Stock  2020/12/18 14:04:41 Watchlist News
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Chairman Michael Bigham sold 18,337 shares of the company’s stock in a transaction on Friday, December 11th. The shares were sold at an average price of $6.95, for a total transaction of $127,442.15. Following the transaction, the chairman now owns 572,580 shares of the company’s stock, valued at $3,979,431. The transaction […]
   Insider Selling: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Chairman Sells $174,882.73 in Stock  2020/12/18 12:14:41 Watchlist News
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Chairman Michael Bigham sold 26,063 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Monday, December 14th. The shares were sold at an average price of $6.71, for a total transaction of $174,882.73. Following the sale, the chairman now directly owns 572,580 shares in the company, valued at approximately […]
   William M. Haskel Sells 4,814 Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock  2020/12/16 12:38:41 Watchlist News
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) General Counsel William M. Haskel sold 4,814 shares of the business’s stock in a transaction dated Friday, December 11th. The stock was sold at an average price of $6.95, for a total transaction of $33,457.30. Following the sale, the general counsel now owns 210,109 shares in the company, valued at $1,460,257.55. […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 パラテック・ファ―マシュ―ティカルズ PRTK Paratek Pharmaceuticals Inc. )

 twitter  (公式ツイッターやCEOツイッターなど)